{"product_id":"liquid-biopsy-in-triple-negative-breast-cancer-a-simple-blood-test-that-could-revolutionize-treatment","title":"Liquid Biopsy in Triple-Negative Breast Cancer: A Simple Blood Test That Could Revolutionize Treatment","description":"\u003cp\u003eLiquid biopsy is emerging as a powerful, noninvasive tool for managing triple-negative breast cancer (TNBC), the most aggressive form of breast cancer. This comprehensive review examines how analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from simple blood draws can help doctors detect early relapse, monitor treatment response, and identify genetic targets for therapy. With TNBC representing about 10%-15% of all breast cancers and current biomarker options limited, liquid biopsy offers a real-time \"snapshot\" of the disease that could transform treatment decisions in both early and metastatic settings—potentially guiding everything from chemotherapy de-escalation to targeted therapy selection.\u003c\/p\u003e\n\n\u003ch1\u003eLiquid Biopsy in Triple-Negative Breast Cancer: A Simple Blood Test That Could Revolutionize Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Understanding Triple-Negative Breast Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#liquid-biopsy\"\u003eWhat Is a Liquid Biopsy?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ctc-early\"\u003eCirculating Tumor Cells in Early TNBC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-response\"\u003eMeasuring Treatment Response Before and After Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ctc-metastatic\"\u003eCirculating Tumor Cells in Metastatic TNBC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#targetable-alterations\"\u003eDetecting Targetable Genetic Alterations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#tumor-heterogeneity\"\u003eDetecting Tumor Heterogeneity\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ctdna-mrd\"\u003ectDNA in Early TNBC: Detecting Minimal Residual Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#neoadjuvant-efficacy\"\u003eUsing Liquid Biopsy to Measure Neoadjuvant Therapy Effectiveness\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-trials\"\u003eOngoing Clinical Trials in Liquid Biopsy for TNBC\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of Current Liquid Biopsy Technology\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eLiquid biopsy uses blood tests to detect ctDNA or circulating tumor cells, giving a real-time view of TNBC. It is noninvasive.\u003c\/li\u003e\n\u003cli\u003eIn early TNBC, ctDNA detection after surgery can identify minimal residual disease and higher relapse risk, as shown before.\u003c\/li\u003e\n\u003cli\u003eIn the I-SPY 2 trial, patients who cleared ctDNA by surgery were more likely to achieve pCR, while persistent ctDNA raised recurrence risk.\u003c\/li\u003e\n\u003cli\u003eLiquid biopsy can detect targetable mutations like PIK3CA in metastatic disease, potentially guiding therapy without tissue biopsy.\u003c\/li\u003e\n\u003cli\u003eLimitations exist: not all tumors shed detectable ctDNA, and trial results vary, so it is not yet a replacement for tissue biopsy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Understanding Triple-Negative Breast Cancer\u003c\/h2\u003e\n\n\u003cp\u003eTriple-negative breast cancer (TNBC) is a particularly challenging form of breast cancer. It is defined by what it \u003cem\u003elacks\u003c\/em\u003e: TNBC tumors test negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Because these three common targets for breast cancer treatment are absent, TNBC does not respond to hormone therapy or HER2-targeted drugs like many other breast cancers do.\u003c\/p\u003e\n\n\u003cp\u003eTNBC represents approximately \u003cstrong\u003e10%-15% of all breast cancers\u003c\/strong\u003e. It is more common in women younger than 40 years and is considered the most aggressive and highly heterogeneous of all breast cancer subtypes. Its aggressive nature means that finding reliable ways to detect the disease early, predict treatment response, and monitor for relapse is absolutely critical.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, treatment decisions for TNBC rely on several prognostic and predictive factors, including immunohistochemical biomarkers such as \u003cstrong\u003eprogrammed death-ligand 1 (PD-L1)\u003c\/strong\u003e and \u003cstrong\u003egermline BRCA1\/2 mutations\u003c\/strong\u003e (inherited mutations in the BRCA1 or BRCA2 genes) which are present in about \u003cstrong\u003e10%-20% of TNBC cases\u003c\/strong\u003e and lead to a condition called homologous recombination deficiency—a defect in the cell's ability to repair DNA damage. Among metastatic TNBC cases, approximately \u003cstrong\u003e20%-38% of patients express PD-L1\u003c\/strong\u003e, a protein that helps tumors evade the immune system and is a target for immunotherapy drugs.\u003c\/p\u003e\n\n\u003cp\u003eAnother important biomarker is the presence of \u003cstrong\u003etumor-infiltrating lymphocytes (TILs)\u003c\/strong\u003e—immune cells that have invaded the tumor tissue. Elevated TIL counts are well established as a favorable prognostic factor, associated with better prognosis, improved response to immunotherapy, and higher rates of \u003cstrong\u003epathologic complete response (pCR)\u003c\/strong\u003e, meaning no cancer cells remain at the time of surgery. The location of these lymphocytes also matters: the best outcomes occur when TILs infiltrate both the tumor epithelium (the layer of cells lining the tumor) and the surrounding stroma (supportive tissue). Conversely, TILs restricted to the tumor margins or completely absent are associated with the worst prognosis. The International Immuno-Oncology Biomarker Working Group recently confirmed the favorable prognostic role of TIL abundance in breast cancer tissue among patients with early-stage TNBC who did not receive adjuvant (post-surgery) or neoadjuvant (pre-surgery) chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eGiven the limitations of existing biomarkers, researchers are increasingly turning to \u003cstrong\u003eliquid biopsy\u003c\/strong\u003e—a noninvasive blood test that can provide real-time information about the tumor's genetic makeup and behavior. This approach could help doctors determine treatment efficacy in both the neoadjuvant and adjuvant settings, detect early relapse, and monitor how the tumor evolves (clonal evolution) during treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"liquid-biopsy\"\u003eWhat Is a Liquid Biopsy?\u003c\/h2\u003e\n\n\u003cp\u003eLiquid biopsy involves analyzing components released by tumors into bodily fluids. These include \u003cstrong\u003ecell-free DNA (cfDNA)\u003c\/strong\u003e—fragments of DNA circulating in the blood—as well as \u003cstrong\u003ecirculating tumor cells (CTCs)\u003c\/strong\u003e (intact cancer cells that have broken away from the tumor), extracellular vesicles (tiny sacs released by cells), and RNA. These components can be detected in blood, urine, cerebrospinal fluid, or bone marrow, offering a minimally invasive window into the disease.\u003c\/p\u003e\n\n\u003cp\u003eWhen mutations are found in cfDNA that match the tumor's genetic profile, this is referred to as \u003cstrong\u003ecirculating tumor DNA (ctDNA)\u003c\/strong\u003e. These mutations serve as highly specific markers for cancer. One fascinating characteristic of ctDNA is that its half-life in circulation ranges from just \u003cstrong\u003e16 minutes to 2.5 hours\u003c\/strong\u003e. This means ctDNA analysis provides a real-time snapshot of the disease at any given moment—unlike traditional tissue biopsies, which capture only a single point in time and a single location within the tumor.\u003c\/p\u003e\n\n\u003cp\u003eCTC levels also carry important prognostic information. In metastatic breast cancer, the number of CTCs can stratify patients into two prognostic groups: \u003cstrong\u003estage IV indolent\u003c\/strong\u003e (slower-growing disease) or \u003cstrong\u003estage IV aggressive\u003c\/strong\u003e, based on a threshold of \u003cstrong\u003e5 or more CTCs per 7.5 ml of blood\u003c\/strong\u003e. Patients in the stage IV indolent group exhibit a longer median overall survival (the time from diagnosis or treatment start until death from any cause).\u003c\/p\u003e\n\n\u003ch2 id=\"ctc-early\"\u003eCirculating Tumor Cells in Early TNBC\u003c\/h2\u003e\n\n\u003cp\u003eSeveral landmark studies have investigated the prognostic value of CTCs in early-stage TNBC. In the adjuvant \u003cstrong\u003eSUCCESS A trial\u003c\/strong\u003e, researchers evaluated the presence of CTCs before chemotherapy and again two years after chemotherapy in \u003cstrong\u003e1,087 patients with high-risk breast cancer\u003c\/strong\u003e. Two years after completing chemotherapy, \u003cstrong\u003e198 patients (about 18%) were CTC positive\u003c\/strong\u003e. This CTC positivity was found to be an independent, statistically significant prognostic factor for poor overall survival (OS) and disease-free survival (DFS—the time after treatment during which no cancer is detected). Importantly, the CTC status at the 2-year follow-up was independent of baseline CTC status. Patients who were CTC positive both at baseline and at the 2-year follow-up had the worst OS and DFS outcomes of all.\u003c\/p\u003e\n\n\u003cp\u003eThese findings matter because they suggest that a simple blood test performed years after initial treatment could identify patients at higher risk of relapse who might benefit from additional or different treatment strategies.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment-response\"\u003eMeasuring Treatment Response Before and After Surgery\u003c\/h2\u003e\n\n\u003cp\u003eIn the neoadjuvant setting (chemotherapy given \u003cem\u003ebefore\u003c\/em\u003e surgery to shrink tumors), CTCs have shown significant clinical value. In patients with nonmetastatic TNBC, the presence of one or more CTCs after completing neoadjuvant chemotherapy (NAC) was associated with significantly decreased overall survival and relapse-free survival.\u003c\/p\u003e\n\n\u003cp\u003eA major meta-analysis conducted by \u003cstrong\u003eBidard et al.\u003c\/strong\u003e pooled data from \u003cstrong\u003e21 studies that detected CTCs using the FDA-cleared CELLSEARCH methodology in 2,030 patients with early breast cancer\u003c\/strong\u003e, of whom \u003cstrong\u003e25.8% had TNBC\u003c\/strong\u003e. The authors demonstrated that CTCs have a prognostic role in patients with early breast cancer treated with NAC, independent of tumor subtype. This means that CTC status adds valuable prognostic information on top of what doctors already know from tumor characteristics, helping to refine current prognostic models.\u003c\/p\u003e\n\n\u003cp\u003eCTC detection after surgery or during adjuvant (post-surgery) therapy has also been associated with poor prognosis. In one study of \u003cstrong\u003e286 women with early TNBC\u003c\/strong\u003e, researchers evaluated CTC levels after surgery. Patients with \u003cstrong\u003emore than 5 CTCs per 7.5 ml of blood\u003c\/strong\u003e experienced worse outcomes compared to those with fewer than 5 CTCs. Specifically, patients with higher CTC counts had a \u003cstrong\u003erecurrence rate of 22.4% at seven days post-surgery\u003c\/strong\u003e—a striking figure that highlights how quickly residual disease can manifest.\u003c\/p\u003e\n\n\u003ch2 id=\"ctc-metastatic\"\u003eCirculating Tumor Cells in Metastatic TNBC\u003c\/h2\u003e\n\n\u003cp\u003eThe prognostic value of CTC enumeration has been demonstrated in metastatic breast cancer using several studies with the FDA-cleared CELLSEARCH methodology, though multiple other detection technologies are now available. In metastatic TNBC, higher CTC counts are consistently linked to poorer outcomes.\u003c\/p\u003e\n\n\u003cp\u003ePatients with CTC counts \u003cstrong\u003eat or above the threshold of 5 per 7.5 ml of blood\u003c\/strong\u003e before treatment, and those who fail to clear these cells during treatment, have significantly worse outcomes compared with patients who maintain a CTC count of less than 5 after starting systemic therapy. Another study showed that patients with CTCs of 5 or more per 7.5 ml, and\/or those who experienced an \u003cstrong\u003eincrease in CTC counts at 3-5 weeks and\/or 6-8 weeks\u003c\/strong\u003e after the start of treatment, had decreased progression-free survival (PFS—the time during and after treatment during which the disease does not worsen) and overall survival.\u003c\/p\u003e\n\n\u003cp\u003eHowever, not all results have been positive. The \u003cstrong\u003eSWOG S0500 trial\u003c\/strong\u003e did not demonstrate improved clinical outcomes in any metastatic breast cancer subtype, including TNBC, when using early CTC-guided treatment changes. This suggests that merely detecting and responding to rising CTC counts does not automatically translate into better survival—therapies must still be effective against the specific cancer biology.\u003c\/p\u003e\n\n\u003cp\u003eIn a retrospective analysis, investigators classified patients into three prognostic subgroups based on baseline CTC enumeration, confirming that patients with higher CTC counts per 7.5 ml of blood had worse outcomes. Additionally, in the \u003cstrong\u003eTBCRC 001 trial\u003c\/strong\u003e, a head-to-head comparison of two CTC enumeration methods—CELLSEARCH and IE\/FC (immunofluorescence\/flow cytometry)—showed high concordance between the techniques. CTC enumeration performed \u003cstrong\u003e7-14 days after treatment initiation was correlated with time-to-progression\u003c\/strong\u003e, suggesting that CTCs may serve as an early marker of response to targeted therapy and may be a more reliable indicator of progression risk than baseline counts.\u003c\/p\u003e\n\n\u003cp\u003eOne particularly concerning feature of CTCs in TNBC is the formation of \u003cstrong\u003emulticellular CTC clusters\u003c\/strong\u003e. These cell clusters are associated with worse outcomes compared to single CTCs. In fact, CTC clusters can promote the development of metastatic disease \u003cstrong\u003e20 to 100 times more frequently than a single CTC\u003c\/strong\u003e. This finding underscores the aggressive biology of TNBC and the importance of detecting and monitoring these clusters.\u003c\/p\u003e\n\n\u003ch2 id=\"targetable-alterations\"\u003eDetecting Targetable Genetic Alterations\u003c\/h2\u003e\n\n\u003cp\u003eBeyond simply counting CTCs, analyzing their molecular characteristics can reveal actionable genetic information. \u003cstrong\u003eAbreu et al.\u003c\/strong\u003e immunoisolated CTCs from a cohort of \u003cstrong\u003e32 patients with stage III and IV TNBC\u003c\/strong\u003e using CELLSEARCH technology. The samples were characterized using a panel of genes related to cancer aggressiveness and plasticity. The expression signature identified in these CTCs was associated with a \u003cstrong\u003ehybrid epithelial-mesenchymal transition (EMT) status\u003c\/strong\u003e—a state in which cancer cells acquire properties that help them invade and spread—and a \u003cstrong\u003estem-like phenotype\u003c\/strong\u003e (cells with the ability to self-renew and seed new tumors). These aggressive cells were detected in \u003cstrong\u003e42% of patients\u003c\/strong\u003e, and 3 of these patients also had CTC clusters. All CTC-positive patients were metastatic at the time of sample collection, and \u003cstrong\u003e26% of these patients had more than 5 CTCs\u003c\/strong\u003e. No correlation was found between the number of CTCs and other clinicopathologic features, suggesting CTC enumeration captures independent biological information. Patients with more than 5 CTCs had worse progression-free survival and overall survival. The cellular plasticity indicated by hybrid EMT and stem cell marker expression in CTCs was associated with poor prognosis and increased tumor aggressiveness.\u003c\/p\u003e\n\n\u003cp\u003eAnother targetable alteration is the \u003cstrong\u003ePIK3CA gene\u003c\/strong\u003e, an actionable cancer gene already demonstrated to be important in hormone receptor-positive metastatic breast cancer. \u003cstrong\u003ePestrin et al.\u003c\/strong\u003e analyzed PIK3CA mutational status within single CTCs isolated from \u003cstrong\u003e39 patients with metastatic breast cancer\u003c\/strong\u003e, 20 of whom had samples enriched with 5 or more CTCs. PIK3CA mutations were identified in \u003cstrong\u003esix patients\u003c\/strong\u003e, and discordance between the PIK3CA status of the primary tumor (wild type, or normal) and the matched CTC (exon 20 mutation) was observed in only \u003cstrong\u003eone patient\u003c\/strong\u003e. While this is a small study, it provides proof of concept that liquid biopsy can potentially guide targeted therapy selection without the need for invasive tissue biopsies.\u003c\/p\u003e\n\n\u003ch2 id=\"tumor-heterogeneity\"\u003eDetecting Tumor Heterogeneity\u003c\/h2\u003e\n\n\u003cp\u003eOne of the greatest challenges in treating TNBC is its heterogeneity—the fact that different parts of a tumor, and different tumor cells within the same patient, can have different genetic profiles. CTCs change their characteristics during tumor cell spreading, mainly through the \u003cstrong\u003eepithelial-mesenchymal transition (EMT) process\u003c\/strong\u003e, which together with the expression of stemness markers can facilitate chemotherapy resistance and promote the capacity to metastasize.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRothé et al.\u003c\/strong\u003e investigated metastatic breast cancer heterogeneity by analyzing CTCs matched with synchronous tumor biopsies from \u003cstrong\u003ethree patients with metastatic breast cancer\u003c\/strong\u003e. Considering tumor mutational burden (TMB) in tumor biopsies from the patient with TNBC, \u003cstrong\u003e38% of all single-nucleotide variants (SNVs)\u003c\/strong\u003e found in the CTC samples were also present in tumor biopsies. This partial overlap reveals that CTCs capture some, but not all, of the genetic diversity present in the tumor—highlighting both the potential and the limits of liquid biopsy for understanding tumor heterogeneity. Importantly, it also suggests that CTCs may reflect subclones (distinct cell populations within a tumor) that are not easily captured by a single tissue biopsy, making liquid biopsy a complementary tool.\u003c\/p\u003e\n\n\u003ch2 id=\"ctdna-mrd\"\u003ectDNA in Early TNBC: Detecting Minimal Residual Disease\u003c\/h2\u003e\n\n\u003cp\u003ePerhaps one of the most exciting applications of liquid biopsy is the detection of \u003cstrong\u003eminimal residual disease (MRD)\u003c\/strong\u003e—the tiny amounts of cancer cells that remain after treatment and are too small to be detected by imaging or standard tests. The \u003cstrong\u003eInternational Expert Consensus Conference in 2017\u003c\/strong\u003e concluded that ctDNA and CTCs are potentially useful biomarkers to guide treatment de-escalation—meaning doctors could safely reduce the intensity of therapy in patients at lower risk of relapse.\u003c\/p\u003e\n\n\u003cp\u003eNotably, ctDNA may be detectable in early breast cancer using high-sensitivity MRD assays. The detection of ctDNA after surgical resection reflects the persistence of \u003cstrong\u003emicrometastatic residual disease\u003c\/strong\u003e—microscopic clusters of cancer cells that have spread beyond the original tumor but are not yet clinically detectable. Therefore, ctDNA could potentially serve as a marker of residual disease in patients with TNBC to guide therapeutic decisions after neoadjuvant therapy.\u003c\/p\u003e\n\n\u003cp\u003eBased on this potential, the \u003cstrong\u003eQ-CROC-03 trial\u003c\/strong\u003e examined patients with TNBC undergoing neoadjuvant chemotherapy, with tumor biopsies carried out before and after chemotherapy as well as blood samples collected before, during, and after NAC to determine molecular factors of response or resistance to standard treatment. The results were striking: a \u003cstrong\u003eslight increase in ctDNA levels was predictive of incomplete pathologic response\u003c\/strong\u003e, and the \u003cstrong\u003eabsence of ctDNA at the presurgical specimen was associated with long-term relapse-free survival and overall survival\u003c\/strong\u003e, with a prognostic value similar to pCR status itself. In other words, a simple blood test before surgery could give patients and doctors a preview of whether the chemotherapy is working as effectively as hoped.\u003c\/p\u003e\n\n\u003ch2 id=\"neoadjuvant-efficacy\"\u003eUsing Liquid Biopsy to Measure Neoadjuvant Therapy Effectiveness\u003c\/h2\u003e\n\n\u003cp\u003eFurther information can be obtained from liquid biopsy to anticipate how well a patient will respond to neoadjuvant chemotherapy. \u003cstrong\u003eMagbanua et al.\u003c\/strong\u003e provided robust evidence regarding the role of ctDNA as a predictive biomarker for response and outcome in the \u003cstrong\u003eI-SPY 2 trial\u003c\/strong\u003e. This groundbreaking study collected blood samples at four time points: before treatment (T0), 3 weeks after starting paclitaxel chemotherapy (T1), between paclitaxel and anthracycline regimens (T2), and right before surgery (T3).\u003c\/p\u003e\n\n\u003cp\u003eThe results were dramatic. At T0 (before treatment), \u003cstrong\u003e73% of patients had detectable ctDNA\u003c\/strong\u003e. This percentage decreased steadily over time: \u003cstrong\u003e35% at T1, 14% at T2, and just 9% at T3\u003c\/strong\u003e (right before surgery). Patients who remained ctDNA positive at T1 were significantly more likely to have residual disease after neoadjuvant chemotherapy (\u003cstrong\u003e83% non-pCR rate\u003c\/strong\u003e) compared with those who cleared their ctDNA (\u003cstrong\u003e52% non-pCR rate\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003cp\u003eEncouragingly, \u003cstrong\u003eall patients who achieved pCR after neoadjuvant chemotherapy were ctDNA negative\u003c\/strong\u003e by the time of surgery. In the group that did not achieve pCR, ctDNA-positive patients had a significantly increased risk of metastatic recurrence. By contrast, ctDNA-negative patients in the non-pCR group had \u003cstrong\u003eexcellent outcomes, similar to those who achieved pCR\u003c\/strong\u003e. This suggests that rising ctDNA before surgery may be an early indicator of increased relapse risk, and could help identify patients who might benefit from treatment intensification before surgery to achieve pCR and prevent distant recurrence.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-trials\"\u003eOngoing Clinical Trials in Liquid Biopsy for TNBC\u003c\/h2\u003e\n\n\u003cp\u003eA substantial number of clinical trials are currently exploring liquid biopsy applications in TNBC. Here are the key studies that are actively enrolling patients:\u003c\/p\u003e\n\n\u003ch3\u003eEarly-Stage TNBC Trials\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSerial ctDNA Monitoring During Adjuvant Capecitabine (NCT04768426)\u003c\/strong\u003e: A phase II trial monitoring ctDNA during adjuvant capecitabine chemotherapy in TNBC patients with residual disease after standard neoadjuvant chemotherapy. The goal is to characterize the ctDNA profile and correlate ctDNA levels with genomic features and survival. Started February 2021, estimated duration 5 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApollo (NCT04501523)\u003c\/strong\u003e: A prospective phase II trial using ctDNA to initiate post-operative boost radiation therapy after neoadjuvant chemotherapy in TNBC. ctDNA-positive patients are randomized to receive boost therapy or standard therapy. Started August 2020, estimated 7-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePERSEVERE (NCT04849364)\u003c\/strong\u003e: A phase II ctDNA-enriched, genomically directed post-neoadjuvant trial. Patients with residual TNBC after preoperative therapy are assigned to one of three arms based on plasma ctDNA positivity and genomic markers. Started August 2021, estimated 13-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZEST (NCT04915755)\u003c\/strong\u003e: A randomized phase III double-blinded study comparing the efficacy and safety of niraparib (a PARP inhibitor) with placebo in participants with either HER2-negative BRCA-mutated breast cancer or TNBC with molecular disease (detectable ctDNA) following surgery or completion of adjuvant therapy. Started June 2021, estimated 8-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSafe-De (NCT05058183)\u003c\/strong\u003e: A trial evaluating safe de-escalation of chemotherapy for stage 1 HER2-positive or TNBC, assessing ctDNA rates in patients treated with surgery alone. Started June 2023, estimated 6-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eASPRIA (NCT04434040)\u003c\/strong\u003e: A single-arm phase II trial of atezolizumab (immunotherapy) combined with sacituzumab govitecan (an antibody-drug conjugate) to prevent recurrence in TNBC patients with residual cancer in the breast or lymph nodes and detectable ctDNA. Started July 2020, estimated 5-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTARMAC (NCT04771871)\u003c\/strong\u003e: A phase II study evaluating treatment response and microRNA profiles in Nigerian women with TNBC receiving standard chemotherapy, examining the potential of circulating microRNA and CTCs as surrogate markers of chemotherapy resistance. Started November 2021, estimated 2-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eArtemis (NCT04803539)\u003c\/strong\u003e: A prospective phase II trial using ctDNA to identify TNBC patients at high relapse risk and initiate post-operative boost therapy. Started April 2021, estimated 7-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBreastImmune03 (NCT03818685)\u003c\/strong\u003e: A multicenter randomized phase II study comparing post-operative radiotherapy plus nivolumab and ipilimumab (both immunotherapies) versus radiotherapy plus capecitabine for TNBC patients with residual disease after NAC. ctDNA detection and molecular subtyping are secondary outcomes. Started July 2019, estimated 5-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOXEL (NCT03487666)\u003c\/strong\u003e: A pilot study of immune checkpoint inhibitor therapy, capecitabine, or combination therapy as adjuvant treatment for TNBC with residual disease following NAC, with ctDNA quantified at multiple time points. Started July 2018, estimated 4-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRESPONSE (NCT05020860)\u003c\/strong\u003e: A phase II trial correlating early clinical response to pathologic outcome in early breast cancer, determining whether a decrease in ctDNA levels from baseline to surgery correlates with clinical or pathologic response. Started April 2023, estimated 6-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtorvastatin Trial (NCT03872388)\u003c\/strong\u003e: A study evaluating atorvastatin (a cholesterol-lowering medication) in patients with stage IIB-III TNBC who did not achieve pCR after neoadjuvant chemotherapy. The primary objective is to determine the proportion of patients with undetectable CTCs at 6 months. Started January 2019, estimated 4-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEliminating Surgery or Radiotherapy (NCT02945579)\u003c\/strong\u003e: A trial evaluating whether surgery or radiotherapy can be safely eliminated after systemic therapy in HER2-positive or TNBC patients, with changes in blood and plasma biomarkers as outcome measures. Started January 2017, estimated 9-year duration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMetastatic TNBC Trials\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGIM25CAPT (NCT05266937)\u003c\/strong\u003e: A phase II trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic PD-L1-positive TNBC. Measures ctDNA variation from baseline to first evaluation and from first evaluation to progression, using the FoundationOne Liquid NGS panel, and analyzes gene expression changes. Started July 2020, estimated 4-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTalazoparib Trial (NCT03990896)\u003c\/strong\u003e: A phase II trial evaluating the effectiveness of talazoparib (a PARP inhibitor) in \u003cstrong\u003e30 patients with metastatic breast cancer who have pathogenic somatic BRCA1\/2 mutations\u003c\/strong\u003e detected in cfDNA. Started November 2021, estimated 3-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEPIK-B3 (NCT04251533)\u003c\/strong\u003e: A phase III, multicenter, randomized, double-blind, placebo-controlled study assessing alpelisib in combination with nab-paclitaxel in patients with advanced TNBC who carry either a \u003cstrong\u003ePIK3CA mutation (study part A)\u003c\/strong\u003e, have \u003cstrong\u003ePTEN loss without PIK3CA mutation (part B1)\u003c\/strong\u003e, or PTEN loss regardless of PIK3CA status (part B2). PIK3CA mutation is determined by ctDNA. Started June 2020, estimated 7-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEribulin + Copanlisib Trial (NCT04345913)\u003c\/strong\u003e: A phase I\/II trial evaluating the safety and efficacy of eribulin combined with copanlisib in metastatic breast cancer, determining ctDNA mutation profiles at baseline, on cycle 2 day 1, and at disease progression to correlate with treatment response. Started March 2021, estimated 3-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNADiR (NCT04837209)\u003c\/strong\u003e: A phase II study of niraparib, dostarlimab, and radiotherapy in metastatic PD-L1-negative or immunotherapy-refractory TNBC, evaluating changes in ctDNA using a patient-specific NGS assay. Started July 2021, estimated 8-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4CAST (NCT04947189)\u003c\/strong\u003e: A phase Ib dose exploration and expansion trial evaluating INO-464 (a novel agent) in combination with chemotherapy in metastatic breast cancer, with gene expression analysis (RNA-seq or single-cell RNA-seq) on tumor biopsies and ctDNA analysis in blood. Started November 2021, estimated 4-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePAveMenT (NCT04360941)\u003c\/strong\u003e: A phase Ib study of palbociclib and avelumab in metastatic androgen receptor-positive TNBC, exploring ctDNA suppression as a potential biomarker of response. Started August 2020, estimated 4-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePembrolizumab + GTX-024 (NCT02971761)\u003c\/strong\u003e: A phase II trial combining pembrolizumab (immunotherapy) with the selective androgen receptor modulator GTX-024 in metastatic androgen receptor-positive TNBC, evaluating the effect on peripheral blood CTCs, ctDNA, tumor-derived exosomes (TEX), and TEX-associated immune biomarkers. Started June 2017, estimated 5-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCFI-400945 + Durvalumab (NCT04176848)\u003c\/strong\u003e: A phase II study of CFI-400945 (a PLK4 inhibitor) combined with durvalumab (immunotherapy) in advanced or metastatic TNBC, measuring immune effects in cfDNA. Started December 2019, estimated 3-year duration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRADIOLA (NCT05340413)\u003c\/strong\u003e: A trial predicting olaparib sensitivity in patients with unresectable locally advanced or metastatic HER2-negative breast cancer with \u003cstrong\u003eBRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutations\u003c\/strong\u003e or low RAD51 foci. A secondary outcome evaluates the capacity of \u003cstrong\u003ectDNA drop after 4 weeks of treatment\u003c\/strong\u003e to predict olaparib efficacy. Started March 2022, estimated 2-year duration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with TNBC, the potential implications of liquid biopsy are far-reaching. This technology could eventually transform cancer care in several key ways:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEarlier relapse detection:\u003c\/strong\u003e Liquid biopsy could detect cancer recurrence months before it becomes visible on imaging scans, potentially allowing earlier intervention when the disease burden is smaller and more treatable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmarter treatment de-escalation:\u003c\/strong\u003e Patients who clear their ctDNA and achieve undetectable levels may be candidates for reduced treatment intensity, sparing them from unnecessary side effects. The 2017 International Expert Consensus Conference already recognized ctDNA and CTCs as potentially useful biomarkers to guide treatment de-escalation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBetter treatment intensification:\u003c\/strong\u003e Conversely, patients who remain ctDNA positive during neoadjuvant therapy may be identified early as non-responders and could be switched to alternative regimens before surgery—potentially improving their chances of achieving pCR.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted therapy matching:\u003c\/strong\u003e The ability to detect actionable mutations like PIK3CA from a blood sample instead of a tissue biopsy could expand access to targeted therapies, especially in metastatic disease where repeat tissue biopsies are often difficult or risky.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReal-time monitoring of clonal evolution:\u003c\/strong\u003e Because ctDNA has a half-life of only minutes to hours, it reflects the tumor's current state. As tumors evolve and develop resistance to therapy, ctDNA can capture these changes, potentially allowing doctors to switch treatments at the moment resistance emerges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of Current Liquid Biopsy Technology\u003c\/h2\u003e\n\n\u003cp\u003eDespite its enormous promise, liquid biopsy is not yet ready to replace traditional tissue biopsies in all settings. Several limitations must be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot all tumors shed detectable DNA or cells:\u003c\/strong\u003e Some TNBC tumors may not release enough ctDNA or CTCs into the bloodstream to be detected. In the I-SPY 2 trial, for example, 27% of patients had no detectable ctDNA even before treatment started.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMixed trial results:\u003c\/strong\u003e The SWOG S0500 trial failed to show that early CTC-guided treatment changes improved outcomes, reminding us that detection alone is not enough—we also need effective therapies to act on the information.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeterogeneity gap:\u003c\/strong\u003e As shown by Rothé et al., only 38% of the genetic variants found in CTCs matched those in tumor biopsies. Liquid biopsy captures only part of the tumor's full genetic picture.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTechnology standardization:\u003c\/strong\u003e Multiple different platforms exist for detecting and analyzing CTCs and ctDNA (CELLSEARCH, IE\/FC, various NGS panels, patient-specific assays). While some show high concordance, there is no universally accepted standard yet.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCost and accessibility:\u003c\/strong\u003e High-sensitivity MRD assays and comprehensive genomic panels remain expensive and are not yet universally available in all clinical settings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients currently navigating a TNBC diagnosis, here is practical advice based on this review:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials:\u003c\/strong\u003e Many of the trials listed above are actively enrolling patients. Ask your oncologist whether you might be eligible for a trial involving liquid biopsy, especially if you have residual disease after neoadjuvant chemotherapy or metastatic TNBC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your biomarkers:\u003c\/strong\u003e If you have TNBC, ask about your PD-L1 status and germline BRCA mutation status. These are currently the most relevant biomarkers for treatment decisions, including immunotherapy and PARP inhibitors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss ctDNA testing options:\u003c\/strong\u003e While not yet standard of care for all TNBC patients, ctDNA monitoring is being increasingly offered in academic medical centers. Ask your doctor whether ctDNA testing could add useful information to your treatment plan.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider TIL evaluation:\u003c\/strong\u003e Tumor-infiltrating lymphocyte counts in your biopsy tissue can provide important prognostic information. Ask your pathologist whether TIL status has been assessed in your biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed:\u003c\/strong\u003e Liquid biopsy is one of the most rapidly evolving areas in oncology. What is experimental today may become standard of care within just a few years. Keep the conversation open with your care team about new developments.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eWhile liquid biopsy is not yet a replacement for standard tissue-based testing, the evidence compiled in this review makes a compelling case that it will soon play a central role in TNBC management. The goal is more precise, personalized care: the right treatment, for the right patient, at the right time.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a liquid biopsy and how is it different from a regular tumor biopsy?\u003c\/h3\u003e\n\u003cp\u003eA liquid biopsy is a blood test that detects cancer-related material, such as circulating tumor DNA or circulating tumor cells, released into the bloodstream. Unlike a tissue biopsy, which samples one spot at one time, a liquid biopsy gives a real-time snapshot of the whole disease and can be repeated easily.\u003c\/p\u003e\n\u003ch3\u003eCan liquid biopsy detect if my triple-negative breast cancer will come back after treatment?\u003c\/h3\u003e\n\u003cp\u003eYes, in early TNBC, detecting ctDNA after surgery or during follow-up can indicate minimal residual disease and a higher risk of relapse. In the SUCCESS A trial, patients who were CTC-positive two years after chemotherapy had worse survival. However, this is not yet standard of care for all patients.\u003c\/p\u003e\n\u003ch3\u003eHow is liquid biopsy used to measure how well chemotherapy is working before surgery?\u003c\/h3\u003e\n\u003cp\u003eIn patients receiving neoadjuvant chemotherapy, blood samples can track ctDNA levels over time. In the I-SPY 2 trial, patients who remained ctDNA-positive early were more likely to have residual disease at surgery. All patients who achieved pCR were ctDNA-negative before surgery, suggesting it predicts response.\u003c\/p\u003e\n\u003ch3\u003eCan liquid biopsy help doctors choose targeted therapy for triple-negative breast cancer?\u003c\/h3\u003e\n\u003cp\u003eAnalyzing circulating tumor cells or ctDNA can reveal genetic alterations like PIK3CA mutations. A small study found PIK3CA mutations in CTCs matched the primary tumor in most cases. This could guide targeted therapy in metastatic disease without needing a tissue biopsy, though more research is needed.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of liquid biopsy for triple-negative breast cancer?\u003c\/h3\u003e\n\u003cp\u003eNot all tumors shed enough DNA or cells to be detected; in I-SPY 2, 27% had no ctDNA before treatment. Also, liquid biopsy captures only part of a tumor's genetic diversity, different test platforms lack standardization, and some trials failed to show survival benefit from changes guided by liquid biopsy.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor about liquid biopsy and biomarkers for my triple-negative breast cancer?\u003c\/h3\u003e\n\u003cp\u003eAsk about your PD-L1 status, germline BRCA mutations, tumor-infiltrating lymphocytes, and whether ctDNA or CTC testing might be useful. Inquire about clinical trials, especially if you have residual disease after neoadjuvant chemotherapy or metastatic TNBC. Consider TIL assessment in your biopsy tissue.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology\" by R. Mazzeo, J. Sears, L. Palmero, S. Bolzonello, A. A. Davis, L. Gerratana, and F. Puglisi.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e ESMO Open, Volume 9, Issue 10, 2024. Published by Elsevier Ltd on behalf of the European Society for Medical Oncology. DOI: https:\/\/doi.org\/10.1016\/j.esmoop.2024.103700\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It was adapted from the original scientific review to make the information accessible to patients and caregivers. All clinical decisions should be made in consultation with a qualified healthcare provider.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47457935425692,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.jp\/products\/liquid-biopsy-in-triple-negative-breast-cancer-a-simple-blood-test-that-could-revolutionize-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}